Gerard Pregenzer, MD
Urology · Enfield, CTNPI 1457647281
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,298 of the $91,606 with a category attached, or 76.7%. Teleflex LLC accounts for 71.9% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $32,190, 2.5 times the $13,072 reported in 2019. Among urology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $267.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$66K
- AbbVie$15K
- Boston Scientific$3K
- Cook Medical LLC$1K
- Neotract Inc.$1K
- Coloplast$974
- plus $4K from 23 others
What the payments were for
- Consulting fees$5,6256%
- Speaking & faculty fees$70,29877%
- Travel & lodging$4,4515%
- Food & beverage$10,88812%
- Education$3440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 82 | $65,890 |
| AbbVie(2 entities) | 38 | $14,885 |
| Boston Scientific | 58 | $3,326 |
| Cook Medical LLC | 10 | $1,055 |
| Neotract Inc. | 10 | $1,045 |
| Coloplast | 18 | $974 |
| Medtronic | 14 | $887 |
| Axonics, Inc. | 13 | $883 |
| C. R. Bard, Inc. & Subsidiaries | 15 | $604 |
| Astellas Pharma US Inc | 19 | $568 |
| Endo Pharmaceuticals Inc. | 8 | $259 |
| Sumitomo Pharma America, Inc. | 20 | $229 |
| Procept Biorobotics Corporation | 2 | $201 |
| Rochester Medical Corporation | 4 | $125 |
| Olympus America Inc. | 4 | $106 |
| Valencia Technologies Corporation | 4 | $106 |
| Myriad Genetic Laboratories, Inc. | 4 | $68 |
| Pfizer | 4 | $64 |
| Endo USA, Inc. | 2 | $53 |
| Agiliti Surgical, Inc. | 2 | $52 |
| 180 Medical, Inc. | 2 | $46 |
| Johnson & Johnson | 2 | $35 |
| Tolmar, Inc. | 1 | $30 |
| Calyxo, Inc. | 1 | $26 |
| Profound Medical Corp. | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$65,731
- BOTOX$14,541
- AMS$910
- Axonics$553
- INTERSTIM$542
- TITAN$521
- GENERAL ERECTILE DYSFUNCTION$479
- SOLYX$404
- Cook Medical Urology$288
- AquaBeam Robotic System$179
- FIBER DUST$150
- Barrigel$129
- GENERAL KIDNEY STONE DISEASE$125
- MYRBETRIQ$125
- LithoVue$125
- XIAFLEX$122
- Cook$118
- Bard Urinary Drainage Bag$103
How this compares
$91,606 in reported general payments places this provider in the 95th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $7,877 |
| Silodosin | 48 | $2,704 |
| Tamsulosin Hcl | 279 | $2,321 |
| Finasteride | 27 | $503 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $266 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $126 |
| Ciprofloxacin Hcl | 31 | $117 |
| Levofloxacin | 31 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $229 | $7,87712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 urology providers in Connecticut.
Other urology in Enfield
- Daniel KellnerNew Haven$122K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
- David CrawleyNew London$25K
- Scott SerelsNorwalk$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.